In today's Pharmaceutical Executive Daily, Eli Lilly's Retatrutide delivers up to 22.6% weight loss in two new Phase III trials, a clinical trial expert discusses why the U.S. is losing trial volume ...
Credo completed the DustPhotonics acquisition, expanding into silicon photonics and creating a vertically integrated AI connectivity platform beyond AECs. Management expects optical products to ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果